499 related articles for article (PubMed ID: 15647189)
1. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.
Furrie E; Macfarlane S; Kennedy A; Cummings JH; Walsh SV; O'neil DA; Macfarlane GT
Gut; 2005 Feb; 54(2):242-9. PubMed ID: 15647189
[TBL] [Abstract][Full Text] [Related]
2. Mucosal bacteria in ulcerative colitis.
Macfarlane S; Furrie E; Kennedy A; Cummings JH; Macfarlane GT
Br J Nutr; 2005 Apr; 93 Suppl 1():S67-72. PubMed ID: 15877898
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis.
Fujimori S; Gudis K; Mitsui K; Seo T; Yonezawa M; Tanaka S; Tatsuguchi A; Sakamoto C
Nutrition; 2009 May; 25(5):520-5. PubMed ID: 19201576
[TBL] [Abstract][Full Text] [Related]
4. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis.
Mawdsley JE; Jenkins DG; Macey MG; Langmead L; Rampton DS
Am J Gastroenterol; 2008 Jun; 103(6):1460-9. PubMed ID: 18510607
[TBL] [Abstract][Full Text] [Related]
5. Synbiotic supplementation containing Bifidobacterium infantis and xylooligosaccharides alleviates dextran sulfate sodium-induced ulcerative colitis.
Sheng K; He S; Sun M; Zhang G; Kong X; Wang J; Wang Y
Food Funct; 2020 May; 11(5):3964-3974. PubMed ID: 32400787
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial.
Tamaki H; Nakase H; Inoue S; Kawanami C; Itani T; Ohana M; Kusaka T; Uose S; Hisatsune H; Tojo M; Noda T; Arasawa S; Izuta M; Kubo A; Ogawa C; Matsunaka T; Shibatouge M
Dig Endosc; 2016 Jan; 28(1):67-74. PubMed ID: 26418574
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease.
Steed H; Macfarlane GT; Blackett KL; Bahrami B; Reynolds N; Walsh SV; Cummings JH; Macfarlane S
Aliment Pharmacol Ther; 2010 Oct; 32(7):872-83. PubMed ID: 20735782
[TBL] [Abstract][Full Text] [Related]
8. Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli.
Kiehne K; Brunke G; Wegner F; Banasiewicz T; Folsch UR; Herzig KH
World J Gastroenterol; 2006 Feb; 12(7):1056-62. PubMed ID: 16534846
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study.
Ishikawa H; Matsumoto S; Ohashi Y; Imaoka A; Setoyama H; Umesaki Y; Tanaka R; Otani T
Digestion; 2011; 84(2):128-33. PubMed ID: 21525768
[TBL] [Abstract][Full Text] [Related]
10. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease.
Matsuda R; Koide T; Tokoro C; Yamamoto T; Godai T; Morohashi T; Fujita Y; Takahashi D; Kawana I; Suzuki S; Umemura S
Inflamm Bowel Dis; 2009 Mar; 15(3):328-34. PubMed ID: 18942752
[TBL] [Abstract][Full Text] [Related]
11. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease.
Bjarnason I; Sission G; Hayee B
Inflammopharmacology; 2019 Jun; 27(3):465-473. PubMed ID: 31054010
[TBL] [Abstract][Full Text] [Related]
12. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome.
Langhorst J; Junge A; Rueffer A; Wehkamp J; Foell D; Michalsen A; Musial F; Dobos GJ
Am J Gastroenterol; 2009 Feb; 104(2):404-10. PubMed ID: 19174795
[TBL] [Abstract][Full Text] [Related]
13. Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial.
González-Hernández LA; Jave-Suarez LF; Fafutis-Morris M; Montes-Salcedo KE; Valle-Gutierrez LG; Campos-Loza AE; Enciso-Gómez LF; Andrade-Villanueva JF
Nutr J; 2012 Oct; 11():90. PubMed ID: 23101545
[TBL] [Abstract][Full Text] [Related]
14. Synbiotic consumption changes the metabolism and composition of the gut microbiota in older people and modifies inflammatory processes: a randomised, double-blind, placebo-controlled crossover study.
Macfarlane S; Cleary S; Bahrami B; Reynolds N; Macfarlane GT
Aliment Pharmacol Ther; 2013 Oct; 38(7):804-16. PubMed ID: 23957631
[TBL] [Abstract][Full Text] [Related]
15. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
16. Bacillus coagulans in Combination with Chitooligosaccharides Regulates Gut Microbiota and Ameliorates the DSS-Induced Colitis in Mice.
Liu Z; Jiang Z; Zhang Z; Liu T; Fan Y; Liu T; Peng N
Microbiol Spectr; 2022 Aug; 10(4):e0064122. PubMed ID: 35900082
[TBL] [Abstract][Full Text] [Related]
17. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis.
Macfarlane S; Furrie E; Cummings JH; Macfarlane GT
Clin Infect Dis; 2004 Jun; 38(12):1690-9. PubMed ID: 15227614
[TBL] [Abstract][Full Text] [Related]
18. Chronic colitis induces expression of β-defensins in murine intestinal epithelial cells.
Rahman A; Fahlgren A; Sundstedt C; Hammarström S; Danielsson A; Hammarström ML
Clin Exp Immunol; 2011 Jan; 163(1):123-30. PubMed ID: 21039426
[TBL] [Abstract][Full Text] [Related]
19. beta-Defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis.
Fahlgren A; Hammarstrom S; Danielsson A; Hammarstrom ML
Clin Exp Immunol; 2004 Aug; 137(2):379-85. PubMed ID: 15270856
[TBL] [Abstract][Full Text] [Related]
20. Synbiotic therapy: a promising new adjunctive therapy for ulcerative colitis.
Haskey N; Dahl WJ
Nutr Rev; 2006 Mar; 64(3):132-8. PubMed ID: 16572600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
